The importance of nonstop treatment after delivery for pregnant women with type 2 diabetes.
There are no reports of very long follow-up studies of pregnant women with type 2 diabetes after delivery. Here we describe cases of Japanese women whom we treated for 20 to 50 years after deliveries to investigate the relationship between blood glucose control and diabetic complications.



In Japan, the prevalence of type 1 diabetes is very low, and we have very few long-term follow-up cases with type 1 diabetes. Therefore, we chose to describe subjects with type 2 diabetes only. We present data on a total of 80 deliveries, 68 cases, treated by one of us (Y.O.) for more than a 50-year period. They are divided into 4 groups based on duration of treatment after delivery: more than 50 years (1 delivery, 1 patient), 40 to 49 years (13 deliveries, 11 patients), 30 to 39 years (19 deliveries, 16 patients), and 20 to 29 years (47 deliveries, 40 patients). Their present average ages in these 4 groups are 77, 72.4, 65.9, and 55.5 years, respectively. Their average HbA1c levels at last visit, in May 2014, are 8.2%, 7.6%.,7.2%, and 8.3%, respectively.



Despite elevated HbA1c levels, they had relatively few complications: 40% (no retinopathy), 43.8% (simple retinopathy), and 12.5% (treated with photocoagulation); 67.5% (no albuminuria), 26.3% (albuminuria), and 6.3% (treated with renal transplantation or hemodialysis). Therefore, even if glycemic control is not ideal, nonstop treatment of Japanese women for type 2 diabetes after deliveries is effective to prevent diabetic complications.



Long-term attention to care of diabetes after pregnancy may be preventive of diabetic complications in other populations as well.
Diabetes Center, Ebina General Hospital, Ebina, Japan.
Yasue
Y
Omori
Diabetes Center, Tokyo Women's Medical University, Tokyo, Japan.
Keiko
K
Yanagisawa
Diabetes Center, Tokyo Women's Medical University, Tokyo, Japan.|Department of Clinical Laboratory, Tokyo Women's Medical University, Tokyo, Japan.
Asako
A
Sato
Diabetes Center, Tokyo Women's Medical University, Tokyo, Japan.
Yasuko
Y
Uchigata
D000328:Adult; D000419:Albuminuria / Q000517:prevention & control*; D015415:Biomarkers / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis; D036861:Delivery, Obstetric; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D003930:Diabetic Retinopathy / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007564:Japan; D011247:Pregnancy; D011379:Prognosis
D015415:Biomarkers; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; C517652:hemoglobin A1c protein, human
diabetic complications; doctor-patient Japan; long-term glycemic control; puerperal